Advanced search for publications
Enter your keywords
Cardiovascular System
This report looks at prescribing trends in primary care for the Cardiovascular System at SICBl and ICB level with particular focus on anticoagulants, antiplatelets and lipid-regulating. Prescribing data is weighted with QoF registers, and also uses HES data to measure prescribing to outcomes. The report also calculates the potential opportunity cost for cardiovascular drugs based […]
Comparison of DOACs for Atrial Fibrillation
Comparison tables are produced for prescribers and medicines management teams. They are designed to assist in prescribing and decision-making within a specific therapeutic area. Several direct oral anticoagulants (DOACs) are licensed for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF). This comparison table allows prescribers and other healthcare […]
Atrial Fibrillation [NICE NG196]: Financial and commissioning impact
In April 2021, NICE published a new guideline NG196 – Atrial fibrillation: diagnosis and management which updates and replaces NICE CG180 (2014). There are a number of new recommendations, which are likely to have both a significant financial impact and potentially affect the way anticoagulation monitoring is managed. This bulletin aims to raise awareness of […]
Cardiovascular outcomes associated with SGLT2 inhibitors (update 2)
The sodium-glucose co-transporter 2 (SGLT2) inhibitors canagliflozin, dapagliflozin, empagliflozin and ertugliflozin are licensed for the improvement of glycaemic control in adults with type 2 diabetes, a population at increased risk of cardiovascular events. Recent clinical trials and cohort studies have assessed whether the SGLT2 inhibitors reduce this risk. Download the full review below to read […]
Cardiovascular outcomes associated with GLP1 receptor agonists (updated)
The glucagon-like peptide 1 receptor agonists (GLP1RAs) dulaglutide, exenatide, liraglutide, lixisenatide, and semaglutide are licensed for the improvement of glycaemic control in adults with type 2 diabetes, a population which is also at increased risk of cardiovascular events. Good quality evidence assessed the effect of these drugs on cardiovascular outcomes. Download the full review below […]